| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
115.21(B) |
| Last
Volume: |
975,365 |
Avg
Vol: |
1,610,683 |
| 52
Week Range: |
$323.57 - $450.8 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
23,137 |
144,475 |
259,873 |
619,971 |
| Total Sell Value |
$10,319,530 |
$60,539,246 |
$102,205,755 |
$209,876,745 |
| Total People Sold |
7 |
12 |
14 |
18 |
| Total Sell Transactions |
7 |
40 |
65 |
130 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Arbuckle Stuart A |
EVP, COO |
• – – |
2022-08-09 |
4 |
AS |
$300.53 |
$1,710,817 |
D/D |
(5,690) |
60,996 |
|
-2% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2022-08-09 |
4 |
OE |
$155.57 |
$299,628 |
D/D |
1,926 |
66,686 |
|
- |
|
| Liu Joy |
SVP, General Counsel |
• – – |
2022-08-09 |
4 |
AS |
$300.00 |
$283,800 |
D/D |
(946) |
13,388 |
|
-2% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-08-08 |
4 |
AS |
$290.32 |
$381,469 |
D/D |
(1,304) |
36,077 |
|
-1% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-08-08 |
4 |
OE |
$187.53 |
$244,539 |
D/D |
1,304 |
37,381 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2022-08-08 |
4 |
AS |
$290.18 |
$181,972 |
D/D |
(621) |
4,661 |
|
-1% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-08-01 |
4 |
D |
$276.62 |
$211,891 |
D/D |
(766) |
40,983 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2022-07-29 |
4 |
AS |
$276.65 |
$173,116 |
D/D |
(621) |
5,282 |
|
11% |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2022-07-25 |
4 |
AS |
$279.44 |
$37,164,481 |
D/D |
(132,079) |
2,423 |
|
12% |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2022-07-25 |
4 |
OE |
$91.05 |
$5,494,139 |
D/D |
60,342 |
134,502 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-07-19 |
4 |
AS |
$286.72 |
$5,156,730 |
D/D |
(17,865) |
36,077 |
|
9% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-07-19 |
4 |
OE |
$155.57 |
$3,096,948 |
D/D |
17,765 |
53,942 |
|
- |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2022-06-24 |
4 |
AS |
$291.30 |
$3,405,006 |
D/D |
(11,689) |
111,153 |
|
6% |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2022-05-31 |
4 |
D |
$271.24 |
$84,356 |
D/D |
(311) |
49,512 |
|
- |
|
| Upadhyay Suketu |
Director |
– • – |
2022-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,558 |
1,558 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2022-05-17 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,672 |
11,052 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-05-16 |
4 |
AS |
$250.56 |
$11,377 |
D/D |
(45) |
41,749 |
|
12% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2022-05-16 |
4 |
AS |
$246.21 |
$33,408 |
D/D |
(133) |
64,760 |
|
12% |
|
| Liu Joy |
SVP, General Counsel |
• – – |
2022-05-16 |
4 |
AS |
$250.77 |
$33,633 |
D/D |
(133) |
14,334 |
|
12% |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2022-05-02 |
4 |
AS |
$255.40 |
$190,842 |
D/D |
(737) |
5,903 |
|
12% |
|
| Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2022-05-02 |
4 |
AS |
$254.87 |
$88,778 |
D/D |
(343) |
42,730 |
|
12% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2022-05-02 |
4 |
AS |
$263.98 |
$80,778 |
D/D |
(306) |
64,760 |
|
12% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-05-02 |
4 |
AS |
$255.47 |
$82,930 |
D/D |
(320) |
41,696 |
|
12% |
|
| Carney Lloyd |
Director |
– • – |
2022-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,449 |
6,850 |
|
- |
|
| Mckenzie Diana |
Director |
– • – |
2022-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,449 |
2,884 |
|
- |
|
3277 Records found
|
|
Page 12 of 132 |
|
|
1.92 (0.44%) 
